HLB Therapeutics continued its upward trend in intraday trading on the 29th, following its upper-limit close the previous trading day. However, the gain is a modest rise, significantly smaller than the previous day's.

As of the morning of the 29th, HLB Therapeutics was trading at 2,620 won, up 40 won (1.55%) from the previous trading day. Compared to the previous day, when the stock soared to its price limit, the intensity of the rise has eased considerably. Still, the fact that the stock has maintained positive territory without turning to a decline on the trading day after a sharp surge has drawn attention to intraday changes in supply and demand.

Upper Limit Driven by FDA Approval News

The previous day, HLB Group shares rallied together on news that a biliary tract cancer treatment developed by HLB's U.S. subsidiary received approval from the U.S. Food and Drug Administration (FDA). HLB Therapeutics also hit the upper limit as buying spread across group stocks in general.

The day's session can be seen as a phase where profit-taking volume from the previous day's surge clashes with additional buying. With the stock currently up only in the 1% range, the situation is closer to a search for direction near the highs rather than a continuation of the strong rally seen the previous day.

Key Points to Watch: Holding the 2,600-Won Level and Trading Volume

The key intraday points to watch are whether the stock holds the 2,600-won level and changes in trading volume. Volatility could increase today depending on whether volume expands again after the previous day's upper-limit close or profit-taking volume grows. In particular, given the sharp short-term price movement, intraday fluctuations could change rapidly.

It is also necessary to check whether the upward trend holds until the close and how HLB Group shares move together overall.

[This article is an informational piece based on publicly available corporate materials, securities firm analyses, and market data. It does not guarantee the rise or fall of any specific stock or recommend buying or selling. Securities firms' target prices and earnings forecasts may change depending on market conditions, and responsibility for losses from investment lies with the investor. AI was used for some sentences and data organization.]